http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
José Aurelio Sosa,José Ramón Laines,David Salvador García,Rafael Hernández,Mark Zappi,Alejandra E. Espinosa de los Monteros 대한환경공학회 2023 Environmental Engineering Research Vol.28 No.3
The energy growing demand and the international environmental policies contribute to the use of renewable energy sources. Among these sources, biogas has acquired great relevance due to its energetic similarity to fuels such as liquefied petroleum gas (LPG) and natural gas (NG). However, biogas needs to be upgraded by removing CO2 and trace gases to obtain biomethane (>85% CH4). This review identifies and classifies seven techniques used in biogas upgrading, reported in academic and scientific publications. A 13-year review period (2008–2021) was considered. Lineal regression was used to analyze the publications number per year. Membranes use represents the largest proportion of publications (33%), while activated carbon (AC) reaches only 22%. However, the use and application of AC obtained the best trend as a publication topic, with a maximum value of R2 = 0.7882. This review documents publish works on obtaining and applying AC in biogas enrichment processes. It includes a review of the characteristics and generation rates of various residual lignocellulosic materials used in the synthesis of AC, the synthesis processes, the characterization techniques, and the final adsorption capacities.
Mari Paz Quesada,David García-Bernal,Diego Pastor,Alicia Estirado,Miguel Blanquer,Ana Mª García-Hernández,José M. Moraleda,Salvador Martínez 한국조직공학과 재생의학회 2019 조직공학과 재생의학 Vol.16 No.6
BACKGROUND: Mesenchymal stromal cells (MSCs) have potent immunomodulatory and neuroprotective properties, and have been tested in neurodegenerative diseases resulting in meaningful clinical improvements. Regulatory guidelines specify the need to perform preclinical studies prior any clinical trial, including biodistribution assays and tumourigenesis exclusion. We conducted a preclinical study of human bone marrow MSCs (hBM-MSCs) injected by intrathecal route in Non-Obese Diabetic Severe Combined Immunodeficiency mice, to explore cellular biodistribution and toxicity as a privileged administration method for cell therapy in Friedreich’s Ataxia. METHODS: For this purpose, 3 9 105 cells were injected by intrathecal route in 12 animals (experimental group) and the same volume of culture media in 6 animals (control group). Blood samples were collected at 24 h (n = 9) or 4 months (n = 9) to assess toxicity, and nine organs were harvested for histology and safety studies. Genomic DNA was isolated from all tissues, and mouse GAPDH and human b2M and b-actin genes were amplified by qPCR to analyze hBM-MSCs biodistribution. RESULTS: There were no deaths nor acute or chronic toxicity. Hematology, biochemistry and body weight were in the range of normal values in all groups. At 24 h hBM-MSCs were detected in 4/6 spinal cords and 1/6 hearts, and at 4 months in 3/6 hearts and 1/6 brains of transplanted mice. No tumours were found. CONCLUSION: This study demonstrated that intrathecal injection of hBM-MSCs is safe, non toxic and do not produce tumors. These results provide further evidence that hBM-MSCs might be used in a clinical trial in patients with FRDA.